KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Prophylactic tranexamic acid for the prevention of postpartum haemorrhage in women with placenta praevia: multicentre, double blind, randomised, placebo controlled, phase 3 trial.

Lizi Zhang, Shilei Bi, Lian Chen, Lili Du, Fang He, Yuan Qiao, Zhongjun Li, Wanjiang Zeng, Xianlan Zhao, Xu Chen, Xiaotian Li, Guifeng Ding, Wei Zhou, Bo Sun, Qing Guo, Xiaoling Guo, Fengmei Jin, Xietong Wang, Qiying Zhu, Qiang Sun, Shaoqing Jiang, Xinghe Wang, Fenge Cai, Yurong Jiang, Jinsong Gao, Zhijian Wang, Zilian Wang, Lanzhen Zhang, Jian-Meng Liu, Liping Huang, Lin Yu, Jingsi Chen, Shuang Zhang, Liona C Poon, Hong-Tian Li, Dunjin Chen, study’s collaborator group

BMJ 393 e089636

PMID42128454
PMCIDPMC13170071
DOI10.1136/bmj-2026-089636
发表日期2026-05-13
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig 1:图注未提示 KM 曲线;Fig 2:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: To investigate whether prophylactic tranexamic acid reduces the incidence of postpartum haemorrhage in women with placenta praevia compared with placebo. DESIGN: Randomised, double blind, placebo controlled, phase 3 study. SETTING: 24 maternity units across China between July 2023 and March 2025. PARTICIPANTS: 1732 women with placenta praevia undergoing caesarean delivery. INTERVENTIONS: Participants were randomly (1:1) assigned to receive prophylactic oxytocin and either tranexamic acid (1 g in 10 mL) or placebo (10 mL normal saline) diluted in 40 mL normal saline intravenously over 10 minutes, initiated within five minutes of umbilical cord clamping. MAIN OUTCOME MEASURES: The primary outcome was postpartum haemorrhage, defined as calculated estimated blood loss ≥1000 mL or as red cell transfusion within two days after delivery. Serious adverse events included thromboembolic events, seizures, acute kidney or liver injury, and maternal death. RESULTS: Of 1732 women with placenta praevia who were randomised, 38 were excluded because they withdrew consent or were determined to be ineligible after randomisation. Primary outcome data were available for 99.8% (1691/1694) of the remaining women. Placenta accreta spectrum was diagnosed in 303 participants (17.9%). The primary outcome occurred in 29.7% (251/845) of the tranexamic acid group and 35.1% (297/846) of the placebo group (relative risk 0.85, 95.2% confidence interval (CI) 0.75 to 0.96; P=0.01). The rates of serious adverse events were similar between the tranexamic acid group and placebo group (0.5% (4 of 837) v 0.5% (4 of 845); relative risk 1.01, 95% CI 0.25 to 4.00). CONCLUSIONS: In women with placenta praevia who underwent caesarean delivery and received prophylactic oxytocin, treatment with tranexamic acid resulted in a statistically significant yet modest reduction in the incidence of postpartum haemorrhage, with no signal of increased serious adverse events. TRIAL REGISTRATION: ClinicalTrials.gov NCT05811676.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Randomisation and treatment. Patients with missing primary outcome data lacked postoperative measurement of packed cell volume. The per protocol population consisted of women in the intention-to-treat group who received tranexamic acid or placebo within five minutes of umbilical cord clamping
非 KM Figure
Fig 2Subgroup analyses for the primary outcome. An interactive version of this graphic is available at https://public.flourish.studio/visualisation/28574562/
非 KM Figure